494 Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas
oleh: David Hong, Lini Pandite, Patrick Schöffski, Lilian Siu, Melissa Johnson, Louis Gonzalez, Bo Ma, Robert Hernandez, Fatima Rangwala, Vladimir Galvao, Irene Brana
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2021-11-01 |
Deskripsi
No description available for this item.